Compare M & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | M | CRSP |
|---|---|---|
| Founded | 1830 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.9B |
| IPO Year | 2003 | 2016 |
| Metric | M | CRSP |
|---|---|---|
| Price | $23.35 | $60.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $20.09 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 6.3M | 1.5M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ 12.08 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $22,621,000,000.00 | $289,590,000.00 |
| Revenue This Year | N/A | $807.72 |
| Revenue Next Year | N/A | $172.52 |
| P/E Ratio | $102.89 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $11.77 | $44.12 |
| 52 Week High | $26.10 | $78.48 |
| Indicator | M | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 64.11 |
| Support Level | $21.80 | $47.48 |
| Resistance Level | $24.22 | $75.06 |
| Average True Range (ATR) | 0.91 | 3.22 |
| MACD | -0.33 | 0.81 |
| Stochastic Oscillator | 12.01 | 74.32 |
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.